Literature DB >> 22030193

The value of procalcitonin level in community-acquired pneumonia in the ED.

Jeong Ho Park1, Jung Hee Wee, Seung Pill Choi, Sang Hoon Oh.   

Abstract

OBJECTIVES: The aim of this study was to investigate the value of procalcitonin (PCT) level in patients with community-acquired pneumonia (CAP) in the emergency department (ED).
METHODS: We conducted a prospective study of patients with CAP in the ED. Patients presenting with a clinical and radiographic diagnosis of CAP were enrolled. The authors measured inflammatory biomarkers. The severity of CAP was assessed by 3 prediction rules. We performed an analysis to assess the value of each biomarker for the prediction of mortality and CAP severity.
RESULTS: A total of 126 patients with CAP are included. Sixteen patients who were older and belonged to high-risk group died within 28 days. Nonsurvivors had significantly increased median PCT level (1.96 vs 0.18 ng/mL) and high-sensitivity C-reactive protein (158.57 vs 91.28 mg/dL) compared with survivors. The median PCT levels were significantly higher in more severe disease, on 3 prediction rules. In regression logistic analyses, the area under the receiver operating characteristic curve of PCT level were 0.828 (95% confidence interval, 0.750-0.889). The addition of PCT level to three prediction rules significantly increased the area under the receiver operating characteristic curve. These results suggest that PCT measurement is more versatile tool for predicting mortality and the severity of disease among patients with CAP in the ED.
CONCLUSIONS: Procalcitonin level is valuable for predicting mortality and the severity of disease among patients with CAP at ED admission. Procalcitonin level as an adjunct to CAP prediction rules may be valuable for prognosis and severity assessment.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22030193     DOI: 10.1016/j.ajem.2011.08.009

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  12 in total

1.  Biomarkers and Disease Severity in Children With Community-Acquired Pneumonia.

Authors:  Todd A Florin; Lilliam Ambroggio; Cole Brokamp; Yin Zhang; Mantosh Rattan; Eric Crotty; Michael A Belsky; Sara Krueger; Thomas N Epperson; Andrea Kachelmeyer; Richard Ruddy; Samir S Shah
Journal:  Pediatrics       Date:  2020-05-13       Impact factor: 7.124

2.  Procalcitonin as a Decision-Supporting Marker of Urgent Biliary Decompression in Acute Cholangitis.

Authors:  Yoon Suk Lee; Kwang Bum Cho; Kyung Sik Park; Ju Yup Lee; Yoo Jin Lee
Journal:  Dig Dis Sci       Date:  2018-02-26       Impact factor: 3.199

Review 3.  Prognostic value of procalcitonin in hospitalized patients with lower respiratory tract infections.

Authors:  Vandack Nobre; Isabela Borges
Journal:  Rev Bras Ter Intensiva       Date:  2016-06

4.  Serial Procalcitonin as a Predictor of Bacteremia and Need for Intensive Care Unit Care in Adults With Pneumonia, Including Those With Highest Severity: A Prospective Cohort Study.

Authors:  Suzanne M McCluskey; Philipp Schuetz; Michael S Abers; Benjamin Bearnot; Maria E Morales; Debora Hoffman; Shreya Patel; Lauren Rosario; Victor Chiappa; Blair A Parry; Ryan T Callahan; Sheila A Bond; Kent Lewandrowski; William Binder; Michael R Filbin; Jatin M Vyas; Michael K Mansour
Journal:  Open Forum Infect Dis       Date:  2017-01-04       Impact factor: 3.835

5.  Effect of procalcitonin on the prognosis of patients with COPD.

Authors:  Chen Gong; Ying Yang; Minli Chen; Zhengfu Xie
Journal:  Biomed Rep       Date:  2020-04-22

6.  Procalcitonin is not an independent predictor of 30-day mortality, albeit predicts pneumonia severity in patients with pneumonia acquired outside the hospital.

Authors:  Takanori Akagi; Nobuhiko Nagata; Hiroyuki Miyazaki; Taishi Harada; Satoshi Takeda; Yuji Yoshida; Kenji Wada; Masaki Fujita; Kentaro Watanabe
Journal:  BMC Geriatr       Date:  2019-01-07       Impact factor: 3.921

Review 7.  Biomarkers of Community-Acquired Pneumonia: A Key to Disease Diagnosis and Management.

Authors:  Elena N Savvateeva; Alla Yu Rubina; Dmitry A Gryadunov
Journal:  Biomed Res Int       Date:  2019-04-30       Impact factor: 3.411

8.  Procalcitonin Kinetics in the First 72 Hours Predicts 30-Day Mortality in Severely Ill Septic Patients Admitted to an Intermediate Care Unit.

Authors:  Filippo Pieralli; Vieri Vannucchi; Antonio Mancini; Elisa Antonielli; Fabio Luise; Lucia Sammicheli; Valerio Turchi; Ombretta Para; Francesca Bacci; Carlo Nozzoli
Journal:  J Clin Med Res       Date:  2015-07-24

Review 9.  Prognostic value of procalcitonin in pneumonia: A systematic review and meta-analysis.

Authors:  Dan Liu; Long-Xiang Su; Wei Guan; Kun Xiao; Li-Xin Xie
Journal:  Respirology       Date:  2015-12-10       Impact factor: 6.424

10.  The association of serum procalcitonin and high-sensitivity C-reactive protein with pneumonia in elderly multimorbid patients with respiratory symptoms: retrospective cohort study.

Authors:  Antonio Nouvenne; Andrea Ticinesi; Giuseppina Folesani; Nicoletta Cerundolo; Beatrice Prati; Ilaria Morelli; Loredana Guida; Fulvio Lauretani; Marcello Maggio; Rosalia Aloe; Giuseppe Lippi; Tiziana Meschi
Journal:  BMC Geriatr       Date:  2016-01-15       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.